cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ultragenyx Pharmaceutical Inc
5 own
9 watching
Current Price
$36.43
$-0.18
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,582.81M
52-Week High
52-Week High
54.98000
52-Week Low
52-Week Low
33.36000
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,582.81M
icon52-Week High54.98000
icon52-Week Low33.36000
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio--
What does the Ultragenyx Pharmaceutical Inc do?
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Children's Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
Read More
How much money does Ultragenyx Pharmaceutical Inc make?
News & Events about Ultragenyx Pharmaceutical Inc.
Zolmax
3 months ago
Deutsche Bank AG grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) by 3.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 861,679 shares of the biopharmaceutical companys stock after purchasing an ...
Globe Newswire
5 months ago
Huang brings decades of expertise to MassBio Board to aid in organizational mission Dennis Huang - Ultragenyx Dennis Huang, chief technical operations officer and executive vice president of gene therapy at Ultragenyx has been named to the board of directors for MassBio BEDFORD, Mass., April 28...
Zolmax
5 months ago
Cantor Fitzgerald initiated coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE Get Rating) in a report released on Wednesday morning, The Fly reports. The firm issued an overweight rating and a $114.00 price objective on the biopharmaceutical companys stock. A number of other analysts have...
Globe Newswire
6 months ago
NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an ...
Globe Newswire
6 months ago
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Eric Crombez, M.D. Eric Crombez, M.D. NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc share price today?
plus_minus_icon
Can Indians buy Ultragenyx Pharmaceutical Inc shares?
plus_minus_icon
How can I buy Ultragenyx Pharmaceutical Inc shares from India?
plus_minus_icon
Can Fractional shares of Ultragenyx Pharmaceutical Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ultragenyx Pharmaceutical Inc stocks?
plus_minus_icon
What is today’s traded volume of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What is today’s market capitalisation of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What percentage is Ultragenyx Pharmaceutical Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ultragenyx Pharmaceutical Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$36.43
$-0.18
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$15.70
$0.47 (3.09 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$13.01
$0.54 (4.33 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.93
$0.38 (0.32 %)
PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
$23.92
$-0.90 (-3.63 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$15.70
$0.47 (3.09 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$13.01
$0.54 (4.33 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.93
$0.38 (0.32 %)
PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
$23.92
$-0.90 (-3.63 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00